Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $284.00.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...

Read Our Latest Analysis on VIR Vir Biotechnology Price Performance NASDAQ VIR opened at $9.98 on Monday. The stock has a market capitalization of $1.37 billion, a PE ratio of -2.55 and a beta of ...

SAN FRANCISCO – Vir Biotechnology, Inc., a $1.5 billion market cap biotech company, announced a change in its executive team with the upcoming departure of Ann (Aine) M. Hanly, Ph.D., and the ...

Another big area of focus for the firm is health tech and life sciences, representing over a quarter of 8VC deals, including the now publicly traded biotechs Senti Bio and Vir. Lonsdale moved 8VC ...